- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07946536
A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management
This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.
Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Izaak Woodley
- E-Mail: izaakwoodley@thecollagen.co
Studienorte
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89101
- Citruslabs
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adults aged 18-55 years at the time of enrollment.
- Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
- Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
- Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
- Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
- Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
- In good general health.
- Resides in the United States.
Exclusion Criteria:
- Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
- Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
- Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
- Currently testing, or plan to in the next 12 weeks, a product for another research study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Glow Shakes Premium Collagen Meal Replacement Arm
|
Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Perceived Nutritional Adequacy
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire |
Baseline to Week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Body Fat Percentage
Zeitfenster: Baseline to Week 12
|
Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale |
Baseline to Week 12
|
|
Change in Muscle Mass
Zeitfenster: Baseline to Week 12
|
Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale |
Baseline to Week 12
|
|
Change in Self-Reported Weight Management and Food Cravings
Zeitfenster: Baseline to Week 12
|
Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced) |
Baseline to Week 12
|
|
Change in Self-Reported Perceived Skin Smoothness
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived skin smoothness score assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Perceived Skin Elasticity
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived skin elasticity score assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Hunger Intensity
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument |
Baseline to Week 12
|
|
Change in Self-Reported Satiety Duration
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument |
Baseline to Week 12
|
|
Change in Self-Reported Food Craving Scores
Zeitfenster: Baseline to Week 12
|
Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced) |
Baseline to Week 12
|
|
Change in Self-Reported Hair Thickness
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived hair thickness assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Hair Health
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived hair health assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Energy Levels
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived energy levels assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Cognitive Focus
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived cognitive focus assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Nail Thickness
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived nail thickness assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Nail Health
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived nail health assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Gut Comfort and Digestive Health
Zeitfenster: Baseline to Week 12
|
Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Metabolism Support
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived metabolism support assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Physical Strength
Zeitfenster: Baseline to Week 12
|
Within-participant change in perceived physical strength assessed via self-report questionnaire |
Baseline to Week 12
|
|
Product Tolerability and Participant Satisfaction
Zeitfenster: Week 12
|
Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire |
Week 12
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- THECO-73657
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .